Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566) reported that the National Medical Products Administration (NMPA) has accepted its marketing application for Jikeqin® (吉可親). According to the announcement dated February 25, 2026, the product is a biosimilar of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, developed under a Category 3.3 biological drug registration for weight management in individuals who have obesity or are overweight.

Jikeqin® imitates the physiological effects of endogenous GLP-1 hormone by promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying. These combined mechanisms help improve blood sugar control and achieve body weight management. Based on results from a randomized, open-label, active-controlled Phase III clinical trial in subjects with obesity, the product demonstrated clinical equivalence to its reference drug in terms of primary efficacy indicators—specifically the percent change in body weight from baseline after 44 weeks of treatment—along with a comparable safety profile.

The announcement indicated that the Company received a drug clinical trial approval notice in January 2024 and completed subject enrollment for the Phase III clinical trial in December 2024. With the study now concluded, the Group has submitted its market approval application materials for review. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. advises shareholders and potential investors to exercise caution when dealing in its shares.

The Board of Directors is chaired by Executive Director and General Manager Fu Hang, with executive directors Zhou Wei, non-executive directors Wu Shihang, Albert Esteve Cruella, Fei Junjie, and Yan Weiting, as well as independent non-executive directors Zhou Zhihui, Ho Mei Yi, and Zhou Demin.